anti-human Thrombopoietin monoclonal antibody Anti-Human 100 µg,Reliatech,101-M647
This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse) immunized with recombinant human Thrombopoietin.
Host
Mouse
Reactivity
Human
Application
WB
Platform ID
BAB063526488

Reliatech
Contact
Tel: +49 (0) 5331 - 8586987
Fax: +49 (0) 5331- 8586989
Email:
Specifications
Scientific Background
Thrombopoietin (Tpo), is a key regulator of megakaryocytopoiesis and thrombopoiesis. It is principally produced in the liver and is bound and internalized by the receptor Tpo R/c-mpl. Defects in the Tpo-Tpo R signaling pathway are associated with a variety of platelet disorders. The 353 amino acid (aa) human Tpo precursor is cleaved to yield the 332 aa mature protein. Mature human Tpo shares approximately 70% aa sequence homology with mouse and rat Tpo. It is an 80 - 85 kDa protein that consists of an N-terminal domain with homology to Erythropoietin (Epo) and a C-terminal domain that contains multiple N-linked and O-linked glycosylation sites. Tissue specific alternate splicing of human Tpo generates multiple isoforms with internal deletions, insertions, and/or C-terminal substitutions. Tpo promotes the differentiation, proliferation, and maturation of MK and their progenitors. Several other cytokines can promote these functions as well but only in cooperation with Tpo. Notably, IL-3 independently induces MK development, although its effects are restricted to early in the MK lineage. Tpo additionally promotes platelet production, aggregation, ECM adhesion, and activation. It is cleaved by platelet-derived thrombin following Arg191 within the C-terminal domain and subsequently at other sites upon extended digestion.
Synonyms
THPO; ML; TPO; MGDF; MKCSF; MPLLG; THCYT1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
Please provide the required information below so that we can quickly source your products.
